Shandong Wohua Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shandong Wohua Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Apr 05

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Mar 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shandong Wohua Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:002107 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	890	43	150	153	N/A
12/31/2023	910	59	127	129	N/A
9/30/2023	978	86	149	155	N/A
6/30/2023	1,004	89	143	149	N/A
3/31/2023	991	106	162	168	N/A
1/1/2023	1,015	107	178	185	N/A
9/30/2022	984	106	171	177	N/A
6/30/2022	931	118	153	160	N/A
3/31/2022	950	139	154	165	N/A
1/1/2022	943	163	181	200	N/A
9/30/2021	967	175	170	215	N/A
6/30/2021	1,037	190	201	257	N/A
3/31/2021	1,041	186	171	230	N/A
12/31/2020	1,006	179	142	197	N/A
9/30/2020	969	185	32	71	N/A
6/30/2020	926	155	30	62	N/A
3/31/2020	891	126	29	60	N/A
12/31/2019	860	96	-1	32	N/A
9/30/2019	857	51	93	130	N/A
6/30/2019	834	39	73	116	N/A
3/31/2019	777	42	53	115	N/A
12/31/2018	774	46	45	108	N/A
9/30/2018	771	42	57	108	N/A
6/30/2018	759	59	61	103	N/A
3/31/2018	754	55	85	104	N/A
12/31/2017	727	57	N/A	124	N/A
9/30/2017	653	67	N/A	93	N/A
6/30/2017	612	59	N/A	88	N/A
3/31/2017	589	52	N/A	91	N/A
12/31/2016	563	49	N/A	73	N/A
9/30/2016	552	53	N/A	79	N/A
6/30/2016	516	56	N/A	72	N/A
3/31/2016	486	66	N/A	122	N/A
12/31/2015	469	71	N/A	133	N/A
9/30/2015	463	87	N/A	131	N/A
6/30/2015	461	79	N/A	140	N/A
3/31/2015	481	62	N/A	73	N/A
12/31/2014	438	43	N/A	40	N/A
9/30/2014	384	22	N/A	25	N/A
6/30/2014	338	13	N/A	8	N/A
3/31/2014	266	11	N/A	2	N/A
12/31/2013	256	11	N/A	15	N/A
9/30/2013	248	10	N/A	18	N/A
6/30/2013	237	9	N/A	20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 002107's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 002107's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 002107's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 002107's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 002107's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 002107's Return on Equity is forecast to be high in 3 years time

Shandong Wohua Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 21%

New major risk - Dividend sustainability

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022)

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Now 22% overvalued

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Now 23% overvalued

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022)

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021)

Now 21% undervalued after recent price drop

High number of new directors

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021)

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020)

New 90-day low: CN¥7.39

New 90-day low: CN¥7.55

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021

Full year 2020 earnings released: EPS CN¥0.31

Full year 2020 earnings released: EPS CN¥0.31

Investor sentiment improved over the past week

New 90-day low: CN¥8.10

New 90-day low: CN¥8.90

Third quarter earnings released

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020

New 90-day low: CN¥9.24

New 90-day low - CN¥10.07

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies